CAR T cell therapies have already shown tremendous promise for treating blood - based cancers, leading the Food and Drug Administration's Oncologic Drugs Advisory Committee to unanimously recommend a Novartis CAR T regimen named tisagenlecleucel for approval to treat pediatric B - cell acute lymphoblastic leukemia, in a landmark ruling in July 2017. (aaas.org)
The trial included 81 patients infused with tisagenlecleucel with 3 or more months of follow - up or earlier discontinuation. (cancernetwork.com)
The product, dubbed tisagenlecleucel (pronounced tis - a-gen-LEK-loo-sell), is the first gene therapy of any kind to be approved in the United States. (discovermagazine.com)